Sahil Khurana, Ajay Pal Singh, Ashok Kumar, Rajeev Nema. Prognostic value of AKT isoforms in non-small cell lung adenocarcinoma[J]. The Journal of Biomedical Research, 2023, 37(3): 225-228. DOI: 10.7555/JBR.36.20220138
Citation:
Sahil Khurana, Ajay Pal Singh, Ashok Kumar, Rajeev Nema. Prognostic value of AKT isoforms in non-small cell lung adenocarcinoma[J]. The Journal of Biomedical Research, 2023, 37(3): 225-228. DOI: 10.7555/JBR.36.20220138
Sahil Khurana, Ajay Pal Singh, Ashok Kumar, Rajeev Nema. Prognostic value of AKT isoforms in non-small cell lung adenocarcinoma[J]. The Journal of Biomedical Research, 2023, 37(3): 225-228. DOI: 10.7555/JBR.36.20220138
Citation:
Sahil Khurana, Ajay Pal Singh, Ashok Kumar, Rajeev Nema. Prognostic value of AKT isoforms in non-small cell lung adenocarcinoma[J]. The Journal of Biomedical Research, 2023, 37(3): 225-228. DOI: 10.7555/JBR.36.20220138
Lung cancer is one of the most prevalent cancers in the world and has a high mortality rate. Lung cancer patients often have a poor prognosis, with a five-year survival rate of only about 16%. The International Agency for Research on Cancer reports that lung cancer was the main cause of cancer deaths in 2020, accounting for 1.80 million deaths. Due to the dismal overall prognosis of lung cancer, there is an urgent need to develop accurate and effective diagnostic tests that target specifically early oncogenic pathways in lung cancer patients to improve their prognosis.
The two principal types of lung cancer are small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC), with NSCLC accounting for around 85% of all lung malignancies[1]. The region frequency and prevalence of the lung disease are controlled by both genotypic and phenotypic exposures. An accurate lung cancer diagnosis is essential for the patient's better survival for two main reasons: appropriate drug selection and effective treatment prediction. Histopathological diagnosis depends on cell shape and the nucleus-to-cytoplasm size ratio to distinguish SCLC from NSCLC. Surgical resection, aggressive or palliative radiation, and neoadjuvant chemotherapy are frequently used to treat lung cancer. In the modern era, gene-targeted treatments against tyrosine kinase inhibitors and antibodies against mutations in driver genes for lung cancer are being developed. Several mutations have been shown to be the most common in lung cancer. For example, mutations in the K-ras proto-oncogene cause 10% to 30% of lung adenocarcinoma (LUAD), while epidermal growth factor receptor mutations are more frequent in squamous cell lung cancer (SqCLC)[2].
Kaplan-Meier plotter (KM plotter) database (http://kmplot.com/analysis/) is a commonly used database for the real-time meta-analysis of published lung cancer microarray datasets to find survival biomarkers[3]. In a number of malignancies, the KM plotter has also been used to discover genes that may serve as possible prognostic indicators for post-progression survival (PPS), progression-free survival (PFS), and overall survival (OS)[3]. Many human malignancies, including lung cancer, have activated and overexpressed AKT isoforms[4]. AKT2 inhibition aids in the suppression of LUAD cell proliferation and colony expansion. Therefore, the significance of AKT isoforms in the diagnosis and prognosis of lung cancer was investigated in the current study. The association between gene specific mRNA expression and OS was analyzed by the KM plotter. Currently, gene expression and survival data from 1927 patients with a follow-up period of 20 years are available. Gene names of AKT isoforms (i.e., AKT1, AKT2, and AKT3) were entered into the KM plotter database to obtain survival plots. The association between mRNA expression levels of different AKT isoforms and the established clinicopathological features was studied. The patient data were linked to OS as well as the sex of the patients.
We found that high AKT1 mRNA expression was not significantly associated with OS in patients with lung cancer (hazard ratio [HR], 1.12; 95% confidence interval [CI], 0.99–1.27, P=0.071) or patients with SqCLC (HR, 0.84; 95% CI, 0.67–1.07; P=0.16), but was significantly associated with a poor OS in patients with LUAD (HR, 1.67; 95% CI, 1.31–2.11; P=2.1e−05 (Fig. 1A–C). High AKT2 mRNA expression was also substantially associated with a poor OS in patients with lung cancer (HR, 1.67; 95% CI, 1.41–1.97; P=1.2e−09) and patients with LUAD (HR, 2.35; 95% CI, 1.82–3.02; P=9.7e−12), but not in patients with SqCLC (HR, 1.35; 95% CI, 0.98–1.86; P=0.062) (Fig. 1D–F). Furthermore, high AKT3 mRNA expression was associated with a poor OS in patients with lung cancer (HR, 1.31; 95% CI, 1.16–1.49; P=2.2e−05) and patients with LUAD (HR, 2.08; 95% CI, 1.64–2.64; P=7.9e−10), but not in patients with SqCLC (HR, 0.97; 95% CI, 0.77–1.23; P=0.82) (Fig. 1G–I).
Figure
1.
Prognostic value of AKT isoforms mRNA expression in non-small cell lung adenocarcinoma.
The prognostic value of AKT1 (A–C), AKT2 (D–F), and AKT3 (G–I) mRNA expressions levels in LC, LUAD, and SqCLC patients. AKT isoforms mRNA levels were classified into low and high expression groups according to the median value. Hazard ratio (HR) indicates the measure of the magnitude of the difference between the two curves from Kaplan-Meier plotter. LC: lung cancer; LUAD: lung adenocarcinoma; SqCLC: squamous cell lung cancer; CI: confidence interval.
Table 1 shows that high expression of all AKT isoforms was significantly associated with a reduced PFS, that high expression of AKT2 and AKT3 was significantly associated with a reduced OS, and that high expression of AKT2 was significantly associated with a reduced FPS. While analyzing the smoking history of the patients, high expression of AKT3 was associated with a poor prognosis and a reduced OS regardless of smoking history (Table 2). Table 3 shows the relevance of these genes with OS in terms of staging. High expression of AKT1, AKT2 and AKT3 was significantly associated with a OS in patients with clinical stage Ⅰ lung cancer, and high expression of AKT3 was also found to be associated with a reduced OS in patients with clinical stage Ⅱ lung cancer. Table 4 shows that high expression of AKT2 and AKT3 were associated with a reduced OS in patients regardless of sex; however, high expression of AKT1 mRNA was not significantly associated with OS in either male or female lung cancer patients.
Table
1.
Correlation between mRNA expression levels of AKT isoforms and survival outcomes in lung caner patients
Isoforms
Progression-free survival
Overall survival
Post-progression survival
Low (N)
High (N)
HR (95% CI)
P-value
Low (N)
High (N)
HR (95% CI)
P-value
Low (N)
High (N)
HR (95% CI)
P-value
AKT1
491
491
1.56 (1.29–1.9)
5.4e−06
964
961
1.12 (0.99–1.27)
7.1e−02
172
172
1.22 (0.95–1.57)
1.3e−01
AKT2
298
298
1.38 (1.05–1.81)
2.0e−02
572
572
1.67 (1.41–1.97)
1.2e−9
69
69
2.10 (1.36–3.24)
6.1e−04
AKT3
491
491
1.63 (1.34–1.98)
6.0e−07
966
959
1.31 (1.16–1.49)
2.2e−5
966
959
1.11 (0.87–1.44)
4.0e−01
The mRNA levels of AKT isoforms were classified into low and high expression groups according to the median value. Hazard ratio (HR) indicates the measure of the magnitude of the difference between the two curves from Kaplan-Meier plotter. CI: confidence interval.
Table
2.
Correlation between mRNA expression levels of AKT isoforms and overall survival of lung cancer patients with or without smoking history
Isoforms
Smoking
Non-smoking
Low (N)
High (N)
HR (95% CI)
P-value
Low (N)
High (N)
HR (95% CI)
P-value
AKT1
102
103
1.15 (0.94–1.42)
1.8e−01
411
409
2.48 (1.37–4.5)
2.0e−03
AKT2
70
71
1.89 (1.24–2.88)
2.7e−03
150
150
1.21 (0.54–2.71)
6.4e−01
AKT3
102
103
1.32 (1.07–1.62)
8.8e−03
411
409
2.28 (1.26–4.13)
5.3e−03
The mRNA levels of AKT isoforms were classified into low and high expression groups according to the median value. Hazard ratio (HR) indicates the measure of the magnitude of the difference between the two curves from Kaplan-Meier plotter. CI: confidence interval.
Table
3.
Correlation between mRNA expression levels of AKT isoforms and overall survival of stage Ⅰ and stage Ⅱ lung cancer patients
Isoforms
Stage Ⅰ
Stage Ⅱ
Low (N)
High (N)
HR (95% CI)
P-value
Low (N)
High (N)
HR (95% CI)
P-value
AKT1
288
289
1.76 (1.34–2.32)
4.5e−05
122
122
1.36 (0.94–1.96)
1.0e−01
AKT2
225
224
2.53 (1.81–3.52)
1.5e−08
82
79
1.5 (0.95–2.37)
7.7e−02
AKT3
290
287
2.2 (1.67–2.91)
1.2e−08
125
119
1.69 (1.17–2.44)
4.4e−04
The mRNA levels of AKT isoforms were classified into low and high expression groups according to the median value. Hazard ratio (HR) indicates the measure of the magnitude of the difference between the two curves from Kaplan-Meier plotter. CI: confidence interval.
In summary, this is the first study to look at the possible involvement of AKT isoforms in prognosis and diagnosis of lung cancer. The current study also explored the association between mRNA levels of AKT isoforms and OS of lung cancer patients with respect to their smoking history, staging of cancer, and sex. The inhibition of the nicotine-activated AKT isoforms pathway may aid in the development of innovative therapeutic techniques for the prevention and treatment of metastatic tumors from smoking-caused lung cancer, which may improve the survival outcome of the patients. Despite the increasing amount of evidence on the altered AKT expression in lung cancer, there is a lack of substantial evidence linking the expression of various AKT isoforms to cancer. The interaction of the selected proteins offers an important information about the evolution of NSCLC and the mechanisms behind cancer incidence, development, metastasis, and drug resistance. The mechanisms behind the actions of these genes must also be investigated, which may assist in the delineation of the predicted network of those genes.
Yours Sincerely,Sahil Khurana1, Ajay Pal Singh2, Ashok Kumar3, Rajeev Nema4,✉1All India Institute of Medical Sciences Bhopal, Bhopal, Madhya Pradesh 462021, India;2Department of Medicine, All India Institute of Medical Sciences Rishikesh, Rishikesh, Uttarakhand 249201, India;3Department of Biochemistry, All India Institute of Medical Sciences Bhopal, Bhopal, Madhya Pradesh 462021, India;4Department of Oncology, 3B Blackbio Biotech India Ltd., Bhopal, Madhya Pradesh 462023, India.✉Corresponding author: Rajeev Neman, R&D Department of Molecular Diagnostics, 3B Blackbio Biotech India Ltd., 7-C, Industrial Area, Govindpura, Bhopal, Madhya Pradesh 462023, India. Tel/Fax: +91-755-4077847/+91-755-4282659, E-mail: rajeevnema07@gmail.com.
Table
4.
Correlation between mRNA expression levels of AKT isoforms and the overall survival of male and female patients
Isoforms
Male
Female
Low (N)
High (N)
HR (95% CI)
P-value
Low (N)
High (N)
HR (95% CI)
P-value
AKT1
552
548
1.06 (0.91–1.24)
4.5e−01
358
356
1.26 (1.00–1.59)
5.2e−02
AKT2
330
329
1.49 (1.22–1.83)
1.4e−04
187
187
2.08 (1.46–2.95)
2.8e−05
AKT3
556
544
1.28 (1.09–1.50)
2.0e−03
358
356
1.34 (1.06–1.69)
1.4e−02
The mRNA levels of AKT isoforms were classified into low and high expression groups according to the median value. Hazard ratio (HR) indicates the measure of the magnitude of the difference between the two curves from Kaplan-Meier plotter. CI: confidence interval.
Clark SB, Alsubait S. Non small cell lung cancer[M]. Treasure Island (FL): StatPearls, 2021.
[2]
de Groot PM, Wu CC, Carter BW, et al. The epidemiology of lung cancer[J]. Transl Lung Cancer Res, 2018, 7(3): 220–233. doi: 10.21037/tlcr.2018.05.06
[3]
Győrffy B, Surowiak P, Budczies J, et al. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer[J]. PLoS One, 2013, 8(12): e82241. doi: 10.1371/journal.pone.0082241
[4]
Liu T, Zhu J, Du W et al. AKT2 drives cancer progression and is negatively modulated by miR-124 in human lung adenocarcinoma[J]. Respir Res, 2020, 21(1): 227. doi: 10.1186/s12931-020-01491-0
Skaria S, Savithriamma SK. Automatic classification of seizure and seizure-free EEG signals based on phase space reconstruction features. J Biol Phys, 2024, 50(2): 181-196.
DOI:10.1007/s10867-024-09654-6
2.
Wong S, Simmons A, Villicana JR, et al. Estimating Patient-Level Uncertainty in Seizure Detection Using Group-Specific Out-of-Distribution Detection Technique. Sensors (Basel), 2023, 23(20): 8375.
DOI:10.3390/s23208375
3.
Wang X, Wang Y, Liu D, et al. Automated recognition of epilepsy from EEG signals using a combining space-time algorithm of CNN-LSTM. Sci Rep, 2023, 13(1): 14876.
DOI:10.1038/s41598-023-41537-z
4.
Ein Shoka AA, Dessouky MM, El-Sayed A, et al. EEG seizure detection: concepts, techniques, challenges, and future trends. Multimed Tools Appl, 2023.
DOI:10.1007/s11042-023-15052-2. Online ahead of print
5.
Al-Hajjar ALN, Al-Qurabat AKM. An overview of machine learning methods in enabling IoMT-based epileptic seizure detection. J Supercomput, 2023.
DOI:10.1007/s11227-023-05299-9. Online ahead of print
6.
Boucher-Routhier M, Thivierge JP. A deep generative adversarial network capturing complex spiral waves in disinhibited circuits of the cerebral cortex. BMC Neurosci, 2023, 24(1): 22.
DOI:10.1186/s12868-023-00792-6
7.
Ebbehoj A, Thunbo MØ, Andersen OE, et al. Transfer learning for non-image data in clinical research: A scoping review. PLOS Digit Health, 2022, 1(2): e0000014.
DOI:10.1371/journal.pdig.0000014
8.
Ahmed MIB, Alotaibi S, Atta-Ur-Rahman, et al. A Review on Machine Learning Approaches in Identification of Pediatric Epilepsy. SN Comput Sci, 2022, 3(6): 437.
DOI:10.1007/s42979-022-01358-9
9.
Yıldız İ, Garner R, Lai M, et al. Unsupervised seizure identification on EEG. Comput Methods Programs Biomed, 2022, 215: 106604.
DOI:10.1016/j.cmpb.2021.106604
10.
Prasanna J, Subathra MSP, Mohammed MA, et al. Automated Epileptic Seizure Detection in Pediatric Subjects of CHB-MIT EEG Database-A Survey. J Pers Med, 2021, 11(10): 1028.
DOI:10.3390/jpm11101028
11.
Saminu S, Xu G, Shuai Z, et al. A Recent Investigation on Detection and Classification of Epileptic Seizure Techniques Using EEG Signal. Brain Sci, 2021, 11(5): 668.
DOI:10.3390/brainsci11050668
12.
Boubchir L. Editorial commentary on special issue of Advances in EEG Signal Processing and Machine Learning for Epileptic Seizure Detection and Prediction. J Biomed Res, 2020, 34(3): 149-150.
DOI:10.7555/JBR.34.20200700
Table
1.
Correlation between mRNA expression levels of AKT isoforms and survival outcomes in lung caner patients
Isoforms
Progression-free survival
Overall survival
Post-progression survival
Low (N)
High (N)
HR (95% CI)
P-value
Low (N)
High (N)
HR (95% CI)
P-value
Low (N)
High (N)
HR (95% CI)
P-value
AKT1
491
491
1.56 (1.29–1.9)
5.4e−06
964
961
1.12 (0.99–1.27)
7.1e−02
172
172
1.22 (0.95–1.57)
1.3e−01
AKT2
298
298
1.38 (1.05–1.81)
2.0e−02
572
572
1.67 (1.41–1.97)
1.2e−9
69
69
2.10 (1.36–3.24)
6.1e−04
AKT3
491
491
1.63 (1.34–1.98)
6.0e−07
966
959
1.31 (1.16–1.49)
2.2e−5
966
959
1.11 (0.87–1.44)
4.0e−01
The mRNA levels of AKT isoforms were classified into low and high expression groups according to the median value. Hazard ratio (HR) indicates the measure of the magnitude of the difference between the two curves from Kaplan-Meier plotter. CI: confidence interval.
Table
2.
Correlation between mRNA expression levels of AKT isoforms and overall survival of lung cancer patients with or without smoking history
Isoforms
Smoking
Non-smoking
Low (N)
High (N)
HR (95% CI)
P-value
Low (N)
High (N)
HR (95% CI)
P-value
AKT1
102
103
1.15 (0.94–1.42)
1.8e−01
411
409
2.48 (1.37–4.5)
2.0e−03
AKT2
70
71
1.89 (1.24–2.88)
2.7e−03
150
150
1.21 (0.54–2.71)
6.4e−01
AKT3
102
103
1.32 (1.07–1.62)
8.8e−03
411
409
2.28 (1.26–4.13)
5.3e−03
The mRNA levels of AKT isoforms were classified into low and high expression groups according to the median value. Hazard ratio (HR) indicates the measure of the magnitude of the difference between the two curves from Kaplan-Meier plotter. CI: confidence interval.
Table
3.
Correlation between mRNA expression levels of AKT isoforms and overall survival of stage Ⅰ and stage Ⅱ lung cancer patients
Isoforms
Stage Ⅰ
Stage Ⅱ
Low (N)
High (N)
HR (95% CI)
P-value
Low (N)
High (N)
HR (95% CI)
P-value
AKT1
288
289
1.76 (1.34–2.32)
4.5e−05
122
122
1.36 (0.94–1.96)
1.0e−01
AKT2
225
224
2.53 (1.81–3.52)
1.5e−08
82
79
1.5 (0.95–2.37)
7.7e−02
AKT3
290
287
2.2 (1.67–2.91)
1.2e−08
125
119
1.69 (1.17–2.44)
4.4e−04
The mRNA levels of AKT isoforms were classified into low and high expression groups according to the median value. Hazard ratio (HR) indicates the measure of the magnitude of the difference between the two curves from Kaplan-Meier plotter. CI: confidence interval.
Table
4.
Correlation between mRNA expression levels of AKT isoforms and the overall survival of male and female patients
Isoforms
Male
Female
Low (N)
High (N)
HR (95% CI)
P-value
Low (N)
High (N)
HR (95% CI)
P-value
AKT1
552
548
1.06 (0.91–1.24)
4.5e−01
358
356
1.26 (1.00–1.59)
5.2e−02
AKT2
330
329
1.49 (1.22–1.83)
1.4e−04
187
187
2.08 (1.46–2.95)
2.8e−05
AKT3
556
544
1.28 (1.09–1.50)
2.0e−03
358
356
1.34 (1.06–1.69)
1.4e−02
The mRNA levels of AKT isoforms were classified into low and high expression groups according to the median value. Hazard ratio (HR) indicates the measure of the magnitude of the difference between the two curves from Kaplan-Meier plotter. CI: confidence interval.
Authors and Reviewers
DownLoad:
